Pazopanib has a manageable safety profile in patients with advanced HCC, and 600 mg was chosen for further development of pazopanib in advanced HCCs. Moreover, pazopanib reduced tumor vessel leakage, as shown by DCE-MRI, indicating a direct effect on HCC vasculature that might be associated with its antitumor activity.
Clinical cancer research : an official journal of the American Association for Cancer Research
Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Clin Cancer Res. 2011 Nov;17(21):6914-23
© Galenicom 1999-2013